US President Donald Trump has unveiled a phased tariff plan on imported generic drugs, with heavy duties set to begin in 2028. The news has caused mixed reactions in Indian pharma stocks as investors assess the impact on profit margins. While the two-year grace period offers temporary relief, the policy forces companies to rethink their long-term reliance on the US market.
US President Donald Trump has proposed a new tariff structure on imported generic drugs, introducing significant uncertainty for the Indian pharmaceutical sector. The plan includes a two-year grace period where tariffs remain at 0% until July 31, 2028. However, the proposal escalates tariffs to 100% in August 2028 and further to 200% starting August 2029. Since India is a major supplier of generic medicines to the United States, accounting for nearly half of all US generic prescriptions, this policy change has direct implications for the industry.
Market Reaction and Stock Volatility
The market response has been mixed, reflecting uncertainty about which companies are most at risk. While the Nifty Pharma Index posted a gain of 3.5% following the announcement, individual stock performances have diverged. Stocks with higher revenue exposure to the US, such as Lupin and Dr. Reddy's Laboratories, have faced more pressure. In contrast, companies with lower direct US exposure, like Divi's Laboratories and Cipla, have shown more resilience. This variance highlights that investors are currently distinguishing between companies based on their vulnerability to US policy shifts.
The Margin and Manufacturing Challenge
A central concern for investors is the potential for margin pressure. Generic drug manufacturing in India currently benefits from lower costs due to affordable labor and access to competitively priced raw materials. If Indian firms are forced to shift manufacturing to the US to avoid these high tariffs, they would face significantly higher operating costs.
Analysts note that setting up new manufacturing facilities in the US, securing regulatory approvals, and reaching full production capacity could take five to seven years. This timeline exceeds the two-year window provided before the 100% tariff kicks in. For many firms, where operating margins in the generic business often range between 10% and 15%, the cost of reshoring could make certain low-margin products economically unviable.
Strategic Shifts and Diversification
To manage this long-term risk, many Indian pharmaceutical companies are already adjusting their business models. Instead of relying solely on plain generic medicines, many are moving toward higher-value products such as specialty medicines, injectables, and biosimilars. These segments generally command better profit margins and are often less susceptible to the pricing pressures seen in basic generics.
Furthermore, several companies are already investing in manufacturing capabilities within the US or acquiring local players as a defensive hedge against potential trade barriers. The success of these strategies depends on the companies' ability to execute these expansions without overloading their balance sheets with debt.
Investors are likely to focus on company-specific updates in the coming quarters. Key monitorables include the percentage of revenue a company derives from the US market, their capital spending plans for US-based facilities, and their progress in expanding into specialty drug portfolios. While the immediate impact is limited by the grace period, the long-term profitability of these firms will depend on their ability to navigate these potential trade barriers.